GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chi Sheng Pharma & Biotech Co Ltd (ROCO:4111) » Definitions » Beneish M-Score

Chi Sheng Pharma & Biotech Co (ROCO:4111) Beneish M-Score : -2.73 (As of Apr. 03, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Chi Sheng Pharma & Biotech Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.73 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Chi Sheng Pharma & Biotech Co's Beneish M-Score or its related term are showing as below:

ROCO:4111' s Beneish M-Score Range Over the Past 10 Years
Min: -2.92   Med: -2.64   Max: -2.09
Current: -2.73

During the past 13 years, the highest Beneish M-Score of Chi Sheng Pharma & Biotech Co was -2.09. The lowest was -2.92. And the median was -2.64.


Chi Sheng Pharma & Biotech Co Beneish M-Score Historical Data

The historical data trend for Chi Sheng Pharma & Biotech Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chi Sheng Pharma & Biotech Co Beneish M-Score Chart

Chi Sheng Pharma & Biotech Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.87 -2.56 -2.53 -2.09 -2.73

Chi Sheng Pharma & Biotech Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.09 -1.78 -2.24 -2.73 -2.73

Competitive Comparison of Chi Sheng Pharma & Biotech Co's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chi Sheng Pharma & Biotech Co's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chi Sheng Pharma & Biotech Co's Beneish M-Score falls into.


;
;

Chi Sheng Pharma & Biotech Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chi Sheng Pharma & Biotech Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.951+0.528 * 0.949+0.404 * 0.9029+0.892 * 1.0986+0.115 * 0.9711
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9803+4.679 * -0.058621-0.327 * 0.8479
=-2.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was NT$327 Mil.
Revenue was 331.465 + 284.253 + 282.519 + 267.2 = NT$1,165 Mil.
Gross Profit was 125.955 + 98.174 + 91.672 + 81.382 = NT$397 Mil.
Total Current Assets was NT$785 Mil.
Total Assets was NT$1,750 Mil.
Property, Plant and Equipment(Net PPE) was NT$762 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$66 Mil.
Selling, General, & Admin. Expense(SGA) was NT$280 Mil.
Total Current Liabilities was NT$373 Mil.
Long-Term Debt & Capital Lease Obligation was NT$7 Mil.
Net Income was 46.73 + 20.172 + 20.603 + 23.128 = NT$111 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 66.459 + 20.328 + 108.892 + 17.519 = NT$213 Mil.
Total Receivables was NT$313 Mil.
Revenue was 269.953 + 261.873 + 265.87 + 263.168 = NT$1,061 Mil.
Gross Profit was 87.933 + 79.641 + 85.647 + 89.882 = NT$343 Mil.
Total Current Assets was NT$804 Mil.
Total Assets was NT$1,766 Mil.
Property, Plant and Equipment(Net PPE) was NT$735 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$62 Mil.
Selling, General, & Admin. Expense(SGA) was NT$260 Mil.
Total Current Liabilities was NT$451 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(327.318 / 1165.437) / (313.301 / 1060.864)
=0.280854 / 0.295326
=0.951

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(343.103 / 1060.864) / (397.183 / 1165.437)
=0.323418 / 0.340802
=0.949

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (784.617 + 761.86) / 1749.63) / (1 - (803.999 + 734.994) / 1766.103)
=0.116112 / 0.128594
=0.9029

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1165.437 / 1060.864
=1.0986

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(61.958 / (61.958 + 734.994)) / (66.301 / (66.301 + 761.86))
=0.077744 / 0.080058
=0.9711

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(280.241 / 1165.437) / (260.221 / 1060.864)
=0.24046 / 0.245292
=0.9803

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((7.09 + 372.801) / 1749.63) / ((0.775 + 451.456) / 1766.103)
=0.217126 / 0.256062
=0.8479

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(110.633 - 0 - 213.198) / 1749.63
=-0.058621

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Chi Sheng Pharma & Biotech Co has a M-score of -2.73 suggests that the company is unlikely to be a manipulator.


Chi Sheng Pharma & Biotech Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Chi Sheng Pharma & Biotech Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Chi Sheng Pharma & Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Shijian Road, Hsin Chu Industrial Park, Hsinchu County, Hukou, TWN, 30316
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.

Chi Sheng Pharma & Biotech Co Headlines

No Headlines